80 results about "Lost Weight" patented technology

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The present invention relates to pharmaceutical combinations for treating or preventing insulin resistance and associated disorders, in particular the use combinations comprising a 4-epimerase inhibitor and a GLP-1 receptor agonist for treating or preventing insulin resistance and associating disorders such as obesity and type-2 diabetes, supressing appetite and / or promoting weight loss.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

The invention relates to a composition with fat burning accelerating and weight losing effects and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problems that an existing classic prescription, namely the three-kernel decoction, is laggard in process and large in dosage are solved. The composition consists of the following traditional Chinese medicine extracts in parts by mass: 1-5 parts of a traditional Chinese medicine extract A, 4-7 parts of a traditional Chinese medicine extract B, 6-8 parts of a traditional Chinese medicine extract C and 3-9 parts of a traditional Chinese medicine extract D. According to the composition disclosed by the invention, the classical prescription of the Sanjing decoction is applied, the effective components are extracted and separated through modern science and technology to obtain an effective extract, the curative effect is exerted through a corresponding proportion, and pharmacodynamic research shows that the traditional Chinese medicine composition disclosed by the invention can achieve the effects of accelerating fat burning and losing weight through the effects of diminishing swelling, clearing damp, draining water and expelling toxin. And the related process is advanced, and the dose is not large.

This item is notebook paper used for recording neonatal jaundice and physiological weight loss.

Provided herein are methods of treating, preventing, or reducing conditions and / or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and / or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a first composition comprising a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures, a crosslinking compound, a foaming agent and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, a second composition comprising citric acid. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The present invention provides nutritional compositions for use in weight loss dietary interventions or in particular weight maintenance after dietary interventions, preferably after low calorie dietary interventions. The nutritional composition comprises one or more amino acids selected from the group consisting of proline, histidine, glycine and / or hydroxyproline, or a combination thereof, which can be used to assist in weight loss in obese subjects that are resistant to weight loss only by means of caloric limiting dietary intervention. In addition, the nutritional composition of the present invention may be used to help maintain the weight loss, particularly after dietary intervention.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The compositions and methods for improving or regulating GLP-1 levels, stimulating GLP-1 secretion, ameliorating metabolism including losing weight, managing glucose or insulin tolerance including stimulating insulin secretion, inhibiting glucagon secretion and reducing fasting glucose levels. The compositions comprise β-aminoisobutyric acid, a physiologically acceptable salt, polymer, ester, or 3-hydroxy-3-methylbutanoic acid, a physiologically acceptable salt, polymer, ester, or tributyrin or tributyrin derivative, or mixture thereof.

The present disclosure provides human inhibin subunit beta E (INHBE) gene-targeting double stranded oligonucleotides, compositions, and methods of using the same, either alone or in combination with additional therapeutics, for preventing and / or treating various INHBE-related disorders, including maintenance of weight loss achieved. In some embodiments, the provided double stranded oligonucleotides comprise certain chemistry modifications, e.g., stereospecific internucleotidic linkage modifications, and have unexpected advantageous properties.

To provide a T cell adaptor therapeutic agent and use thereof.SOLUTION: The T-cell adaptor is a T-cell bispecific antibody comprising a first binding domain that binds to BCMA on the target cell surface and a second binding domain that binds to CD3 on the T-cell surface. The bispecific antibody is well tolerated, can effectively block the binding of BCMA to its receptor APRIL, and has no adverse effects such as weight loss.SELECTED DRAWING: Figure 1

An integrated weight management system comprising a biocompatible intraoral device and personalized software is disclosed. The device, configured for insertion into the user's mouth, creates a separation between the tongue and teeth causing the stomatognathic system, limiting hunger cues associated with food anticipation. Sensors coupled to the device detect its removal and insertion, enabling the system to track adherence to meal plans and weight loss progress. The software utilizes machine learning algorithms to generate personalized meal plans, food intake timing, nutrition education, and exercise routines based on user preferences, dietary restrictions, and weight loss goals. The system analyzes user data to provide progress reports, adjust meal plans, and send alerts to promote accountability and compliance. This comprehensive approach addresses both physiological and psychological aspects of weight management, offering a novel and effective solution for achieving and maintaining a healthy weight.

The present invention provides novel compounds that are peptide hormone analogs and are useful for treating disorders such as diabetes and obesity.The compounds of the general sequence listed herein have tailored profiles of potency at the GIP receptor.Regarding in vivo properties, administration of exemplary peptides of the present invention has been shown to result in improved weight loss in animal models.Preferred compounds achieve this without significantly reducing food intake.

Methods and uses are presented in which a therapeutically effective unit dose of dodecanedioic acid (DDDA or DC12) is administered for an extended period of time to improve a subject's lipid metabolism. Preferred dosage units comprise no more than 5% of the subject's standard daily caloric intake and improvements in metabolism are associated with weight loss and / or reduction of visceral fat.

One patent obtained in the earlier stage is that the line peptide COX52-69 is cyclized to realize an oral administration route. The invention discovers that the cyclic peptide, namely C * LLPAGWV-[N-Me-Leu]-SHLDSYKKREC *, has the effect of reducing the body weight. In the invention, a diet-induced obesity (DIO) model is established by feeding C57BL / 6J mice with high-fat feed (45% of fat for energy supply) for 14 weeks. After a DIO mouse is obtained, a 17-week administration experiment is carried out by using a PBS buffer solution and a Rybelsus solution as a contrast, and observation finds that the COX52-69 cyclic peptide can relieve weight gain caused by DIO, so that the weight of the DIO mouse is reduced, and multiple metabolic indexes can be improved. Results show that the COX52-69 cyclic peptide has practical application in weight loss and weight gain prevention processes, and also has reagent application in improvement of some metabolic indexes of obese people.

The present application mainly relates to a kind of composition for reducing fat and losing weight and its preparation method and application, belong to the field of biotechnology.The composition of the present application includes Cordyceps flower fruit body granules 30-60 parts, Morel fruit body granules 5-20 parts, bitter buckwheat flour 10-25 parts, mulberry leaf water extract 10-25 parts, Huangjing water extract 5-21 parts and Cassia seed water extract 1-6 parts.The above raw materials are mixed to obtain the composition of the present application.The composition of the present application can improve the blood lipid level of hyperlipidemia, inhibit the increase of body weight, reduce the volume of white adipose cells, inhibit the deposition of liver lipid, reverse the damage of liver tissue and liver function, effectively reduce fat and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

Provided herein are compositions, formulations, and methods of treatment for weight loss and satiety improvement for a subject in need thereof, including a human subject in need thereof. The compositions may be used to improve satiety, insulin sensitivity and the microbiome in a subject in need thereof. The composition may further used for weight management and / or in mammals, including humans.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

The present application discloses a two-arm branched fatty acid side chain, a receptor agonist modified therewith, and a use thereof. By adjusting the number and structure of side chain arms of the fatty acid chain, optimizing the type of a core molecule, and using the fatty acid chain to modify a receptor agonist, the present application significantly improves the physical and chemical stability of the receptor agonist and the therapeutic effect of the receptor agonist on reducing blood glucose and body weight. The fatty acid chain and the receptor agonist modified therewith disclosed in the present application can reduce blood glucose levels and improve sugar tolerance and has the effects of controlling appetite, food intake, and caloric intake, increasing energy consumption, preventing weight gain, promoting weight loss, and reducing excess body weight. In addition, the fatty acid chain and the receptor agonist modified therewith disclosed in the present application have relatively long half-life and can effectively prolong in vivo drug actions.

The invention relates to the technical field of breeding, in particular to a composition for relieving vomitoxin harm of weaned piglets and a preparation method and application of the composition. The composition is prepared from the following components in parts by weight: 50 to 70 parts of glucurolactone, 10 to 15 parts of cynarin, 20 to 40 parts of scutellaria baicalensis flavone, 10 to 20 parts of stevia rebaudiana extract and 80 to 120 parts of a carrier. The composition can be used for effectively relieving the symptoms of diarrhea, weight loss and intestinal dysfunction of weaned piglets.

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

The invention further relates to compounds, pharmaceutical compositions and methods for treating a subject for sexual function, such as sexual disorder or sexual dysfunction (SD), for inducing subject weight loss, for effectuating weight maintenance by a subject, whether or not the weight maintenance is used alone or in combination with a subject's weight loss, and / or for improving a subject's subjective state of well-being, self-esteem and / or self-confidence. Examples of SD contemplated by the present invention include but are not limited to female sexual disorder (FSD), female sexual arousal disorder (FSAD), female sexual interest / arousal disorder (FSIAD), female hypoactive sexual desire disorder (HSDD), female orgasmic disorder (FOD), female sexual pain disorder (FSPD), sexual interest arousal disorder (SIAD), male sexual disorder (MSD), male hypoactive sexual desire disorder (MSHDD), erectile dysfunction (ED), Pyronine's disease (PD), male premature ejaculation (MPE), male delayed ejaculation (MDE), male decreased libido (MDL), male dry orgasm (MDO).

This invention discloses a probiotic protein V2016 and its application in the preparation of drugs for treating obesity, belonging to the field of biomedical technology. This invention provides a probiotic protein V2016, the amino acid sequence of which is shown in SEQ ID NO.1. Verification has shown that protein V2016 can efficiently and stably bind to the intestinal receptor ICAM-2, thereby significantly upregulating GLP-1 expression, mediating weight loss, reduced fat accumulation, and improved glucose tolerance; simultaneously, it can also reduce hepatic lipid deposition and inflammation, and promote thermogenesis activation in adipose tissue; at the intestinal microecological level, protein V2016 can improve the intestinal microenvironment, promote the enrichment of butyrate-producing bacteria in the intestine, thereby playing a role in regulating metabolism. In summary, the protein V2016 provided by this invention can be applied to the development of novel functional foods or weight-loss drugs.

The present invention provides novel compounds which are peptide hormone analogs and are useful in the treatment of conditions such as diabetes and obesity. Compounds of the general sequence listed in the specification have a tailored profile with respect to potency characteristics for GIP receptors. Administration of example peptides of the invention has been demonstrated in animal models about in vivo characteristics to result in increased weight loss. Preferred compounds achieve this without significantly reducing food intake.

This invention discloses the application of psoralen in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease.

The disclosure relates to methods for losing weight by administering a therapeutically effective amount of 5-methoxy-2-aminoindan or a pharmaceutically acceptable salt thereof to a subject in need thereof for a period of time sufficient to increase basal energy expenditure. The disclosure also relates to methods for treating fatty liver disease by administering a therapeutically effective amount of 5-methoxy-2-aminoindan or a pharmaceutically acceptable salt thereof to a subject in need thereof.

A model for predicting the net energy available to a companion animal from a pet food is provided. The model can be used to determine the appropriate amount of a food to feed a companion animal, and / or to provide feeding guidelines for any type of food, for any companion animal, and such methods are provided. Also provided are methods of packaging food for a companion animal, animal, and methods of maintaining a desired weight, or effecting weight loss, in a companion animal.

The present disclosure provides human inhibin subunit beta E (INHBE) gene-targeting double stranded oligonucleotides, compositions, and methods of using the same, either alone or in combination with additional therapeutics, for preventing and / or treating various INHBE-related disorders, including maintenance of weight loss achieved. In some embodiments, the provided double stranded oligonucleotides comprise certain chemistry modifications, e.g., stereospecific internucleotidic linkage modifications, and have unexpected advantageous properties.

Obesity and type 2 diabetes are among the greatest health challenges facing not only the U.S, but the entire world. Weight loss significantly improves morbidity and mortality associated with obesity and associated metabolic diseases, such as type 2 diabetes. Provided herein are compositions and methods for treating obesity and metabolic diseases or disorders.